Pharming Group N.V. (AMS:PHARM)

Netherlands · Delayed Price · Currency is EUR

1.095

-0.016 (-1.40%)

Jun 16, 2026, 5:36 PM CET

Revenue by Segment

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2020	FY 2018	FY 2017	FY 2016
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Jan '20 Jan 1, 2020	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016
Ruconest®	317.92M	252.24M	227.13M	205.62M	-
Ruconest® Growth	26.04%	11.05%	10.46%	-	-
Joenja®	58.21M	44.96M	18.18M	-	-
Joenja® Growth	29.47%	147.28%	-	-	-
Recombinant Human C1 Esterase Inhibitor Business	-	-	-	-	198.87M
Recombinant Human C1 Esterase Inhibitor Business Growth	-	-	-	-	-6.27%
Total	376.13M	297.20M	245.32M	205.62M	198.87M
Total Growth	26.56%	21.15%	19.30%	3.39%	-6.27%

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2020	FY 2018	FY 2017	FY 2016
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Jan '20 Jan 1, 2020	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016
United States (US)	361.75M	287.15M	239.11M	200.08M	193.42M
United States (US) Growth	25.98%	20.09%	19.50%	3.44%	-4.57%
Europe and The Rest of The World	14.39M	10.05M	6.21M	5.54M	5.45M
Europe and The Rest of The World Growth	43.15%	61.88%	12.08%	1.61%	-
Total	376.13M	297.20M	245.32M	205.62M	198.87M
Total Growth	26.56%	21.15%	19.30%	3.39%	-6.27%